Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
Ono's antisense therapy is to begin its first pivotal trial.
A trial of one KRAS G12D inhibitor is halted early, while that of another sees tox troubles.
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
But now it must show that varseta-M can move into a registrational trial.
